Navigation Links
CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting
Date:11/20/2007

- Election of New Directors

- Appointment of Company Officers

- Decrease in Authorized Shares

- Approval of 3

- 1 Stock Split

SCHENECTADY, N.Y., Nov. 20 /PRNewswire/ -- CardioMag Imaging, Inc. (CMI) is pleased to announce that at its Annual Shareholder Meeting held on November 7 2007, Monica R. Brettler, Tush P. Nikollaj, Carl H. Rosner and Arthur Roth were elected to serve as Board members of CardioMag Imaging. Also approved at the November 7th Annual Shareholders Meeting was the proposal to reduce the number of authorized common shares of the Company from 50 million to 12 million.

CardioMag additionally announced that its Board of Directors has approved a three-for-one split of the Company's common stock coincident with the reduction in the number of authorized shares. Each shareholder of record at the close of business on November 9, 2007 will receive two additional shares for every outstanding share held on the record date.

Carl H. Rosner, Chairman and CEO, described actions approved by both the shareholders of CardioMag and its Board of Directors and outlined the new strategic approach to strongly pursue early insurance company reimbursement for its non-invasive, radiation-free cardiac test that the Company was instituting under the direction of its new President - Tush Nikollaj. He also was pleased to announce the reappointment of Alexander Bakharev - Sr. Vice President of New Product Development, Robert S. Sokolowski - Vice President of Business Development, Barbara Polidore - Controller, and Catherine Arduini - Corporate Secretary.

Visit our website - http://www.cardiomag.com

Safe Harbor Statement: CardioMag Imaging Inc. is a development stage company. The statements presented in this press release which are not historical facts are forward
'/>"/>

SOURCE CardioMag Imaging, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...AM, November 30 Biopharmaceutical ...st patients have been enrolled in its,multinationa...tudy is,designed to show reduction in transplant r... allogeneic stem cell transplantation with a misma...ents eligible for an allogeneic,stem cell transpla...
(Date:11/30/2009)...., Nov. 30 BioMarin Phar...hat the Food and Drug Administration (FDA) has gra...ne (3,4-DAP), amifampridine phosphate, for the rar...rome (LEMS). 3,4-DAP has previously received orph...2009, the Committee for Medicinal Products for Hum...
(Date:11/30/2009)...NGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTec...nology, and medical-device research and,developmen... the United States,announced that it had been sel...9 list for the fifth consecutive year. The list re...,s technology, media, and telecommunications,indus...
(Date:11/28/2009)... The Vanuatu National Advisory Committee on Clima...unication (SNC) Project in collaboration with the ...d. of New Zealand have generated preliminary clima...m the background for the country’s SNC repor... Climate Change (UNFCCC). , ...
Breaking Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4
...ipitor Will Cause Market Share of Statins to, Drop...m Decision Resources, WALTHAM, Mass., Sept. 11 D...arch and advisory firms for pharmaceutical and,hea...el angiogenic agents,including a future blockbuste...ic treatment of peripheral arterial disease (PAD)....
... Track for Initiation Later This Year - - Confer... Time -, SAN DIEGO, Sept. 11 Arena Pharmaceutica...ndependent Echocardiographic,Data Safety Monitorin...op,the ongoing pivotal Phase 3 trial, BLOOM (Behav...nd Obesity Management). The BLOOM trial is,evaluat...
... in Atrial Fibrillation, EP Mapping and ... ST. LOUIS, Sept. 11 Stereotaxis, Inc.,(Nasdaq: ...dures have been,performed using the Stereotaxis sy...gnet-guided navigational technology intended to he...mplex arrhythmias and,perform other interventional...
Other Biology Technology:Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 6Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 2Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 3
(Date:11/30/2009)..., CLEMSON Clemson University researchers Ron Fal...ironmental Protection Agency grant to study the sa...ons located deep below the earth,s surface. , Wi...els believed to be the leading cause of global war...st promising alternatives for reducing emissions u...
(Date:11/30/2009)... This release is available in German . , T...llaborative Research Centres as of 1 January 2010....rants Committee in Bonn. The new centres will init... million. In addition, 20 percent overhead funding... project. The centres, research topics range from ...
(Date:11/30/2009)... The Editors of The Journal of Experimental Biolo...from Centre National de la Recherche Scientifique ...s the winner of this year,s JEB Outstanding Pape...n outstanding achievement and is intended to encou...JEB Editor-in-Chief, and adds that ,we truly appr...
Breaking Biology News(10 mins):DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009 5678 1Physical scientists at Arizona State University will apply laws of physics in cancer fight 60067 1Physical scientists at Arizona State University will apply laws of physics in cancer fight 60067 2Physical scientists at Arizona State University will apply laws of physics in cancer fight 60067 3Physical scientists at Arizona State University will apply laws of physics in cancer fight 60067 4Chemosensitivity of cancer cells depends on their protein dependency 10521 1Chemosensitivity of cancer cells depends on their protein dependency 10521 2
...sed to detect chemical warfare agents and explosiv...ty of Manchester to treat hospital patients with l...chers are using a sensor, commonly used to detect ...agnosing lung disease. , The microDMx TM sensor,... develop a new technique which is able to detect ,...
...rotein most commonly used in the world for therape...e and to avoid risk of a heart attack, its adminis... occurrence. It is used for haemorrhages, burns, s...oms of malnutrition or dehydration, chronic infect...umption in Spain is about 10 tons but, at a worldw...
...forest might not have yielded pots of gold, but it...ne: some of the globe,s richest soil that can tran...,s not all. Scientists have a method to reproduce ...rk earths -- and say it can pull substantial amoun...n dioxide in the Earth,s atmosphere, helping to pr...
Other Biology News:Chemical warfare agent detection technology used to treat lung disease 2Human albumin from tobacco plants 2Human albumin from tobacco plants 3GPSDB, the free Gene and Protein Synonyms DataBase 2
Chicken Anti-Human DCTD Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Cow Xanthine Oxidase Polyclonal Antibody, HRP Conjugated from Abcam
Chicken Anti-Human LYZL6 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-UBC12 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: